Validation of the MaiRa Preeclampsia Test for Screening Early/Late Preeclampsia in First and Second Trimesters
Preeclampsia (PE) is a major obstetric complication with severe short- and long-term consequences for both mother and fetus. Early detection is critical to mitigate PE-related morbidity and mortality. Effective screening tools are needed to identify women at risk, enabling timely preventive and therapeutic interventions. Current screening methods primarily target placental biomarkers like sFLT1 and PlGF, which are limited to short-term predictions near symptom onset. Existing first-trimester assessments that…
Conditions studied
Preeclampsia (PE)
About this study
Preeclampsia (PE) is a major obstetric complication with severe short- and long-term consequences for both mother and fetus. Early detection is critical to mitigate PE-related morbidity and mortality. Effective screening tools are needed to identify women at risk, enabling timely preventive and therapeutic interventions. Current screening methods primarily target placental biomarkers like sFLT1 and PlGF, which are limited to short-term predictions near symptom onset. Existing first-trimester assessments that incorporate maternal factors and Doppler metrics remain constrained by low sensitivity (\<41%) in compliance with NICE and ACOG guidelines. Recent advancements in cell free RNA (cf-RNA) analysis have revealed potential in first-trimester PE prediction. Findings from the PREMOM study (NCT04990141) established a molecular profile for early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE) through cfRNA analysis, culminating in the development of the MaiRa Preeclampsia Test (Maternal Advanced and Innovative Preeclampsia Risk Assessment), which demonstrated high predictive performance for first- and second-trimester screening. The current study hypothesizes that the MaiRa Preeclampsia Test is generalizable, maintaining its predictive accuracy in an independent cohort.
Interventions
- Procedure: Peripheral blood collection — Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data will also be compiled.
Primary outcomes
- Validation of the MaiRa Preeclampsia Test for first-trimester screening (9-14 weeks) of EOPE (From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.)
Eligibility information
Study locations
- Hospital General Universitario Dr. Balmis, Alicante, Alicante 03010 Spain
- Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona 08025 Spain
- Hospital Comarcal de Vinaròs, Vinaròs, Castellón 12500 Spain
- Hospital Universitario Puerta del Mar, Cadiz, Cádiz 11009 Spain
- Hospital Universitario A Coruña, A Coruña, La Coruña 15006 Spain
- Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid 28850 Spain
- Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia 30120 Spain
- Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife 38320 Spain
- Hospital de Manises, Manises, Valencia 46940 Spain
- Hospital Universitario Doctor Peset, Valencia, Valencia 46017 Spain
Showing 10 of 11 reported sites. See the official listing for all locations.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-26.